What is it used for?
MOUNJARO® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.MOUNJARO® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- tirzepatidetirzepatide
- Form and strength
- INJECTION, SOLUTION · 2.5 mg / 0.5 mL; INJECTION, SOLUTION · 5 mg / 0.5 mL; INJECTION, SOLUTION · 7.5 mg / 0.5 mL; INJECTION, SOLUTION · 10 mg / 0.5 mL; INJECTION, SOLUTION · 12.5 mg / 0.5 mL; INJECTION, SOLUTION · 15 mg / 0.5 mL; INJECTION, SOLUTION · 4.17 mg / 1 mL; INJECTION, SOLUTION · 8.33 mg / 1 mL; INJECTION, SOLUTION · 12.5 mg / 1 mL; INJECTION, SOLUTION · 16.7 mg / 1 mL; INJECTION, SOLUTION · 20.8 mg / 1 mL; INJECTION, SOLUTION · 25 mg / 1 mLINJECTION, SOLUTION · 2.5 mg / 0.5 mL; INJECTION, SOLUTION · 5 mg / 0.5 mL; INJECTION, SOLUTION · 7.5 mg / 0.5 mL; INJECTION, SOLUTION · 10 mg / 0.5 mL; INJECTION, SOLUTION · 12.5 mg / 0.5 mL; INJECTION, SOLUTION · 15 mg / 0.5 mL; INJECTION, SOLUTION · 4.17 mg / 1 mL; INJECTION, SOLUTION · 8.33 mg / 1 mL; INJECTION, SOLUTION · 12.5 mg / 1 mL; INJECTION, SOLUTION · 16.7 mg / 1 mL; INJECTION, SOLUTION · 20.8 mg / 1 mL; INJECTION, SOLUTION · 25 mg / 1 mL
- Manufacturer / applicant
- ELI LILLY AND COMPANYELI LILLY AND COMPANY
Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses: Single-dose Pen or Vial …Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses: Single-dose Pen or Vial …
Safety and clinical review
In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell …In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell …
- Risk of Thyroid C-Cell TumorsRisk of Thyroid C-Cell Tumors
- Acute PancreatitisAcute Pancreatitis
- Hypoglycemia with Concomitant Use of Insulin Secretagogues or InsulinHypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
- Hypersensitivity ReactionsHypersensitivity Reactions
- Acute Kidney Injury Due to Volume DepletionAcute Kidney Injury Due to Volume Depletion
- Severe Gastrointestinal Adverse ReactionsSevere Gastrointestinal Adverse Reactions
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Mounjaro used for?
MOUNJARO® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.MOUNJARO® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Mounjaro should I ask about?
INJECTION, SOLUTION · 2.5 mg / 0.5 mL; INJECTION, SOLUTION · 5 mg / 0.5 mL; INJECTION, SOLUTION · 7.5 mg / 0.5 mL; INJECTION, SOLUTION · 10 mg / 0.5 mL; INJECTION, SOLUTION · 12.5 mg / 0.5 mL; INJECTION, SOLUTION · 15 mg / 0.5 mL; INJECTION, SOLUTION · 4.17 mg / 1 mL; INJECTION, SOLUTION · 8.33 mg / 1 mL; INJECTION, SOLUTION · 12.5 mg / 1 mL; INJECTION, SOLUTION · 16.7 mg / 1 mL; INJECTION, SOLUTION · 20.8 mg / 1 mL; INJECTION, SOLUTION · 25 mg / 1 mLINJECTION, SOLUTION · 2.5 mg / 0.5 mL; INJECTION, SOLUTION · 5 mg / 0.5 mL; INJECTION, SOLUTION · 7.5 mg / 0.5 mL; INJECTION, SOLUTION · 10 mg / 0.5 mL; INJECTION, SOLUTION · 12.5 mg / 0.5 mL; INJECTION, SOLUTION · 15 mg / 0.5 mL; INJECTION, SOLUTION · 4.17 mg / 1 mL; INJECTION, SOLUTION · 8.33 mg / 1 mL; INJECTION, SOLUTION · 12.5 mg / 1 mL; INJECTION, SOLUTION · 16.7 mg / 1 mL; INJECTION, SOLUTION · 20.8 mg / 1 mL; INJECTION, SOLUTION · 25 mg / 1 mL
Read the primary sourceWhat determines the price of Mounjaro?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Mounjaro?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.